Overall, receiving simultaneous immunotherapies leads to higher rates of irAEs than monotherapy, and anti-CTLA-4 tend to have more frequent and severe irAEs because CTLA-4 interaction is less specific to T cells and cancer cells than anti-PD-1/anti-PD-L1 [33–35]. Here, CD274 is linked to cancer.